10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||||||||||||||
| ||||||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
GILEAD SCIENCES, INC. | |||
Ticker: GILD Fiscal Year: 2014 | |||
Consolidated Statements of Income | |||
Period Ending Dec 31, 2014 10-K (Filed: Feb 25, 2015) | |||
| (In Millions) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2014 | Dec 31, 2013 | Dec 31, 2012 | |
| Revenues [Abstract] | |||
| Product sales | $ 24,474 | 10,804 | 9,398 |
| Royalty, contract and other revenues | 416 | 398 | 304 |
| Total revenues | 24,890 | 11,202 | 9,702 |
| Costs and Expenses [Abstract] | |||
| Cost of goods sold | 3,788 | 2,859 | 2,471 |
| Research and development expenses | 2,854 | 2,120 | 1,760 |
| Selling, general and administrative expenses | 2,983 | 1,699 | 1,461 |
| Total costs and expenses | 9,625 | 6,678 | 5,692 |
| Income from operations | 15,265 | 4,524 | 4,010 |
| Interest expense | (412) | (307) | (361) |
| Other income (expense), net | 3 | (9) | (37) |
| Income before provision for income taxes | 14,856 | 4,208 | 3,612 |
| Provision for income taxes | 2,797 | 1,151 | 1,038 |
| Net income | 12,059 | 3,057 | 2,574 |
| Net loss attributable to noncontrolling interest | 42 | 18 | 18 |
| Net income attributable to Gilead | 12,101 | 3,075 | 2,592 |
| Net income per share attributable to Gilead common stockholdersbasic | 7.95 | 2.01 | 1.71 |
| Shares used in per share calculationbasic | 1,522 | 1,529 | 1,515 |
| Net income per share attributable to Gilead common stockholdersdiluted | 7.35 | 1.81 | 1.64 |
| Shares used in per share calculationdiluted | 1,647 | 1,695 | 1,583 |
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
GILEAD SCIENCES, INC. | |||
Ticker: GILD Fiscal Year: 2014 | |||
Consolidated Statements of Comprehensive Income | |||
Period Ending Dec 31, 2014 10-K (Filed: Feb 25, 2015) | |||
| (In Millions, except shares in actual) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2014 | Dec 31, 2013 | Dec 31, 2012 | |
| Net income | $ 12,059 | 3,057 | 2,574 |
| Other Comprehensive Income (Loss) [Abstract] | |||
| Net foreign currency translation gain (loss), net of tax | (9) | (44) | 11 |
| Available-for-sale Securities [Abstract] | |||
| Net unrealized gain, net of tax impact of $0, $4, $(1) | 1 | 5 | 1 |
| Reclassifications to net income, net of tax impact of $0, $0, and $1 | (1) | 0 | 33 |
| Net change | 0 | 5 | 34 |
| Cash Flow Hedges [Abstract] | |||
| Net unrealized gain (loss), net of tax impact of $16, $4 and $2 | 430 | (60) | (62) |
| Reclassification to net income, net of tax impact of $(4), $(1), and $(2) | 4 | 21 | (87) |
| Net change | 434 | (39) | (149) |
| Other comprehensive income (loss) | 425 | (78) | (104) |
| Comprehensive income | 12,484 | 2,979 | 2,470 |
| Comprehensive loss attributable to noncontrolling interest | 42 | 18 | 18 |
| Comprehensive income attributable to Gilead | 12,526 | 2,997 | 2,488 |
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
GILEAD SCIENCES, INC. | |||
Ticker: GILD Fiscal Year: 2014 | |||
Consolidated Statements of Cash Flows | |||
Period Ending Dec 31, 2014 10-K (Filed: Feb 25, 2015) | |||
| (In Millions, except shares in actual) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2014 | Dec 31, 2013 | Dec 31, 2012 | |
| Net Cash Provided by (Used in) Operating Activities [Abstract] | |||
| Net income | $ 12,059 | 3,057 | 2,574 |
| Adjustments to Reconcile Net Income to Net Cash Provided by Operating Activities [Abstract] | |||
| Depreciation expense | 125 | 103 | 83 |
| Amortization expense | 925 | 242 | 195 |
| Stock-based compensation expense | 360 | 252 | 209 |
| Excess tax benefits from stock-based compensation | (482) | (279) | (114) |
| Tax benefits from exercise and vesting of stock-based awards | 484 | 285 | 113 |
| Deferred income taxes | (236) | (98) | (39) |
| Change in fair value of contingent consideration | 22 | 59 | 69 |
| Other | 79 | 46 | (3) |
| Changes in Operating Assets and Liabilities [Abstract] | |||
| Accounts receivable, net | (2,578) | (315) | 198 |
| Inventories | 143 | (343) | (350) |
| Prepaid expenses and other assets | (371) | (170) | (129) |
| Accounts payable | (289) | (98) | 117 |
| Income taxes payable | 533 | 30 | (68) |
| Accrued liabilities | 2,013 | 312 | 317 |
| Deferred revenues | 31 | 22 | 23 |
| Net cash provided by operating activities | 12,818 | 3,105 | 3,195 |
| Net Cash Provided by (Used in) Investing Activities [Abstract] | |||
| Purchases of marketable securities | (2,107) | (257) | (1,245) |
| Proceeds from sales of marketable securities | 807 | 494 | 528 |
| Proceeds from maturities of marketable securities | 52 | 78 | 45 |
| Other investments | (18) | 0 | (25) |
| Acquisitions, net of cash acquired | 0 | (379) | (10,752) |
| Capital expenditures | (557) | (190) | (397) |
| Net cash used in investing activities | (1,823) | (254) | (11,846) |
| Net Cash Provided by (Used in) Financing Activities [Abstract] | |||
| Proceeds from debt financing, net of issuance costs | 7,932 | 0 | 2,144 |
| Proceeds from convertible note hedges | 2,543 | 2,774 | 214 |
| Purchases of convertible note hedges | (26) | 0 | 0 |
| Proceeds from issuances of common stock | 331 | 313 | 466 |
| Repurchases of common stock | (5,349) | (582) | (667) |
| Repayments of debt and other long-term obligations | (4,779) | (4,440) | (1,839) |
| Payment to Settle Warrants Related to Convertible Notes | (4,093) | (1,040) | 0 |
| Excess tax benefits from stock-based compensation | 482 | 279 | 114 |
| Payment of contingent consideration | (101) | 0 | 0 |
| Contributions from noncontrolling interest | 35 | 152 | 131 |
| Net cash provided by (used in) financing activities | (3,025) | (2,544) | 563 |
| Effect of exchange rate changes on cash and cash equivalents | (56) | 2 | 8 |
| Net change in cash and cash equivalents | 7,914 | 309 | (8,080) |
| Cash and cash equivalents at beginning of period | 2,113 | 1,804 | |
| Cash and cash equivalents at end of period | 10,027 | 2,113 | 1,804 |
| Supplemental Cash Flow Information [Abstract] | |||
| Interest Paid, Net of Amount Capitalized | 330 | 238 | 249 |
| Income taxes paid | 2,060 | 1,051 | 1,101 |
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||
GILEAD SCIENCES, INC. | ||
Ticker: GILD Fiscal Year: 2014 | ||
Consolidated Balance Sheets | ||
Period Ending Dec 31, 2014 10-K (Filed: Feb 25, 2015) | ||
| (In Millions, except shares in actual) | ||
| As of | As of | |
| Dec 31, 2014 | Dec 31, 2013 | |
| Assets [Abstract] | ||
| Assets, Current [Abstract] | ||
| Cash and cash equivalents | $ 10,027 | 2,113 |
| Short-term marketable securities | 101 | 19 |
| Accounts receivable, net of allowances of $356 at December 31, 2014 and $252 at December 31, 2013 | 4,635 | 2,182 |
| Inventories | 1,386 | 1,697 |
| Deferred tax assets | 508 | 331 |
| Prepaid taxes | 391 | 398 |
| Prepaid expenses | 194 | 166 |
| Other current assets | 472 | 91 |
| Total current assets | 17,714 | 6,997 |
| Assets, Noncurrent [Abstract] | ||
| Property, plant and equipment, net | 1,674 | 1,166 |
| Long-term portion of prepaid royalties | 466 | 199 |
| Long-term deferred tax assets | 236 | 190 |
| Long-term marketable securities | 1,598 | 439 |
| Intangible assets, net | 11,073 | 11,900 |
| Goodwill | 1,172 | 1,169 |
| Other long-term assets | 731 | 519 |
| Total assets | 34,664 | 22,579 |
| Liabilities and Stockholders' Equity [Abstract] | ||
| Current liabilities [Abstract] | ||
| Accounts payable | 955 | 1,256 |
| Accrued government and other rebates | 2,316 | 1,018 |
| Accrued compensation and employee benefits | 316 | 243 |
| Income taxes payable | 105 | 11 |
| Other accrued liabilities | 1,452 | 1,071 |
| Deferred revenues | 134 | 111 |
| Current portion of long-term debt and other obligations, net | 483 | 2,697 |
| Total current liabilities | 5,761 | 6,407 |
| Liabilities, Noncurrent [Abstract] | ||
| Long-term Debt, net | 11,921 | 3,939 |
| Long-term income taxes payable | 562 | 162 |
| Long-term deferred tax liabilities | 51 | 83 |
| Other long-term obligations | 535 | 179 |
| Commitments and contingencies (Note 11) | ||
| Temporary Equity [Abstract] | ||
| Equity component of currently redeemable convertible notes (Note 10) | 15 | 64 |
| Stockholders' Equity [Abstract] | ||
| Preferred stock, par value $0.001 per share; 5 shares authorized; none outstanding | 0 | 0 |
| Common stock, par value $0.001 per share; shares authorized of 5,600 at December 31, 2014 and December 31, 2013; shares issued and outstanding of 1,499 at December 31, 2014 and 1,534 at December 31, 2013 | 2 | 2 |
| Additional paid-in capital | 2,391 | 5,386 |
| Accumulated other comprehensive income (loss) | 301 | (124) |
| Retained earnings | 12,732 | 6,106 |
| Total Gilead stockholders equity | 15,426 | 11,370 |
| Noncontrolling interest | 393 | 375 |
| Total stockholders equity | 15,819 | 11,745 |
| Total liabilities and stockholders equity | 34,664 | 22,579 |
| External Links | |
| GILEAD SCIENCES, INC. (GILD) Fiscal Year 2014 | |
| Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
| Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
| Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |